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Background: ESBL-producing bacteria are a clinical problem in the management of diseases caused by these
pathogens. Worldwide, systemic infections with BL enzymes are evolving by mutations from classical bla genes in
an intensified manner and they continue to be transferred across species.
Results: E.cloacae BF1417 isolate and its transconjugants gave positive results with the DDST, suggesting the
presence of ESBL. Sequence analysis revealed a blaSHV-ESBL-type gene that differs from the gene encoding SHV-1 by five
point mutations resulting in three amino acid substitutions in the coding region: C123R, I282T and L286P.
This novel SHV-type enzyme was designated SHV-128. The conjugation tests and plasmid characterization showed
that the blaSHV-128 is located on a conjugative plasmid IncFII type. Expression studies demonstrated that the
above mutations participated in drug resistance, hydrolysis of extended spectrum β-lactam and the change of
the isoelectric point of the protein.
Conclusion: These findings underscore the diversity by which antibiotic resistance can arise and the evolutionary
potential of the clinically important ESBL enzymes. In addition, this study highlights the need for systematic
surveillance of ESBL-mediated resistance as well as in clinical areas and communities.
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In Gram-negative bacteria, ESBL-mediated resistance is
emerging worldwide and is mainly due to the mobilization
of Ambler class A β-lactamase, the largest structural ⁄ evo-
lutionary group [1,2]. Most ESBLs are variants of the clas-
sical TEM-1 and SHV-1 ß-lactamases, with one or more
amino acid substitutions that confer resistance to broad-
spectrum cephalosporins and aztreonam. These changes
alter the catalytic site allowing the hydrolysis of oxyimino
cephalosporins and monobactams [3,4].
SHV β-lactamases are prevalent in Gram-negative
bacteria. These enzymes were originally reported in
Klebsiella pneumoniae clinical isolate and they ex-
hibits an overall preference for hydrolysis of sulfhydryl
in cephalosporin drug (hence the SHV name) [5,6].
SHV-1 can hydrolyse penicillin and cephalosporins but* Correspondence: boursaamel@yahoo.fr
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unless otherwise stated.not expanded-spectrum antibiotics such as oxyimino
cephalosporins and monobactams. Point mutations in
the SHV-1 gene were the first to be reported, and are
frequently associated with several mobilization events
in blaSHV gene resulting in new β-lactamase variants
[7]. At present, more than 150 SHV variants have been
identified and novel ESBLs continue to be reported at
an alarming rate (http://www.lahey.org/studies/). Rap-
idly, genes encoding these enzymes have been mutated
and transferred to other Gram-negative bacteria in-
cluding Enterobacter cloacae that is commonly found in
hospitals and causes a wide range of infections, such as
lower respiratory tract infections, urinary tract infections
and meningitis [8]. This microorganism is the most com-
monly isolated member of the Enterobacteriaceae that
possess a chromosomally encoded AmpC β-lactamase that
plays an important role in resistance to antibiotics [9].
However, several reports have demonstrated that these
species can acquire and express genes encoding extended-
spectrum β-lactamase [10].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Bourouis et al. Journal of Biomedical Science  (2015) 22:27 Page 2 of 7Until today, β-lactamase enzymes with an extended
spectrum activity against the majority of β-lactams evolve
at an alarming rate and new β-lactamases that are trans-
ferred among species on plasmids with multiple resistance
factors are also being described continuously. In this study,
we report a phenotypic and molecular characterization of a




E. cloacae BF1417 was recovered during an epidemio-
logical study at the Military Hospital of Tunis, Tunisia.
This strain was isolated from a stool culture of a 75-year-
old man hospitalized for renal failure in the intensive care
unit at the Military hospital of Tunis. The studied strain
was selected on the basis of its multidrug-resistance pheno-
type (MDR) and it was identified using MALDI-TOF MS
system, the VITEK 2 (bioMérieux, La Balme-les-Grottes,
France) and the API 20 E system (bioMérieux, Marcy
l’Etoile, France). E. coli DH5α competent cells were used as
host for cloning and for the transformation experiments.
Streptomycin-resistant E. coli HB101 was used as a recipi-
ent for conjugation tests.
Resistance transfer and plasmid characterization
The transferability of ESBLs genes between the clinical
isolate and the recipient was performed by conjugation
experiments using the filter-mating procedure [11].
Transconjugants growing on selection plates were sub-
jected to DDST to confirm the resistance transfer and
the presence of the ESBL phenotype. Plasmid DNA of
the clinical isolate and its transconjugants were ex-
tracted with a plasmid extraction kit Promega Midi Plas-
mid Prep according to the manufacturer’s instructions.
For determination of plasmid size, the plasmid DNAs
from the transconjugants and the clinical isolate were
subjected to electrophoresis on 0.7% agarose gel. Plas-
mid incompatibility groups were determined by PCR-
based replicon typing according to Carattoli et al. [12].
Antimicrobial susceptibility testing and ESBL detection
The antimicrobial susceptibility of E. cloacae BF1417 to β-
lactams, fluoroquinolones, phénicol, aminoglycosides and
other drugs was performed on Mueller–Hinton (MH) agar
plates by the standard disk diffusion procedure as de-
scribed previously. Minimum inhibitory antibiotics con-
centrations were determined by the serial dilution method
and results were interpreted according to the Clinical
and Laboratory Standards Institute guidelines [13]. ESBL
phenotype was confirmed by the double disk synergy test
(DDST) in presence of cloxacillin at 250 μg/ml in Mueller–
Hinton agar (Biorad, Marnes-la- Coquette, France).Analytical isoelectric focusing (IEF)
The β-lactamase contents of the clinical strain and its
transconjugants were analyzed by isoelectric focusing on
a pH-3 to 10 ampholine polyacrylamide (Bio-rad®,
France) gel containing starch 0.5% at a voltage of 100
to 300 in a 111 Mini IEF Cell (Bio-Rad®, France). β-
lactamases with known pIs were used as standards:
TEM- 1(pI 5.4),TEM-2 (pI 5.6), TEM-3 (pI 6.3) and
SHV- 1(pI 7.6) [14].
β-lactamase essay and IC50 determination
E. coli DH10B/PBF1417 was grown overnight at 37°C in
Trypto-Casein Soy broth (TSB) (Diagnostics, Pasteur,
France) supplemented with cefotaxim, 20 μg/ml. The cells
were harvested by centrifugation and washed once in
25 mM potassium-sodium phosphate buffer (pH 7) and
resuspended in 1 ml of the same buffer. For preparation of
cell free extract, the cells were ruptured by ultrasonic
treatment in a UP 400 S sonicator at 4°C. Cell debris was
removed by centrifugation at 10,000 rpm for 10 min in a
Hettich centrifuge R32 Rotor. The supernatant was loaded
onto a Sephadex G-75 column (95 by 2 cm; Pharmacia,
Sweden) equilibrated with the same buffer. Eluted frac-
tions were collected and tested spectrophotometrically for
β-lactamase activity with 50 μM cephaloridine as the sub-
strate at 255 nm. Active fractions were pooled, dialyzed
against 25 mM Tris–HCl buffer, and then applied to a
polyacrylamide slab gel electrophoresis under non-
denaturing conditions as previously described [15]. After
incubation with cefotaxime 20 μg/ml, β-lactamase activity
was identified as a clear band appeared in the gel back-
ground. The detected band was then cut and eluted in
1 ml of the phosphate buffer (0.25 M; pH 7.4) at 4°C
under moderate agitation overnight. The purity of en-
zymes was estimated by using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis [16]. Hydrolysis of the
substrates was monitored by following the absorbance
variations as described previously using a CARY 50 Bio
UV-visible spectrophotometer connected to a microcom-
puter. For the partially purified enzyme, relative hydrolysis
rate (Vmax) was determined graphically using Linweaver-
Burk representation [17]. For determination of inhibitor
effects, rates of hydrolysis of 1 mM cephalothin were de-
termined in the presence of various concentrations of cla-
vulanic acid and sulbactam. EDTA was used for 1 mM as
concentration. In these experiments, the proteic extract
was preincubated with the inhibitors for 10 min before
the addition of cephalothin. The inhibitory concentration
that allowed the reduction of β-lactamases activities of
50% was graphically fixed as previously described [18].
PCR amplification and DNA sequencing
Detection of gene sequences coding for β-lactamase en-
zymes was performed with the plasmid DNA as template
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blaOXA and AmpC (Table 1). Positive sample was re-
amplified using Pfu DNA polymerase (Promega, USA).
The amplifications were performed on 100 μl samples
containing 5 μl DNA, 0.2 nmol of each primers, 20 nmol
deoxynucleoside triphosphate (dNTP), 3 U Pfu DNA
polymerase) and 10 μl 10X buffer (20 mM MgSO4), and
dimethyl sulfoxide (7%). PCR mapping of the genetic en-
vironment surrounding the blaSHV gene was performed
with primers specific for insertion sequence IS26
(primers IS26-1 and IS26-2) combined with forward and
reverse primers for blaSHV gene as previously described
[19]. The experiment was performed on a DNA thermal
cycle (AB Applied Biosystem 2720). The PCR products
were separated in 1, 2% agarose gel and visualised with
UV. Amplified DNA fragments were sequenced on both
strands and the nucleotide sequences and their deduced
amino acid sequences were compared with those in-
cluded in the GenBank database using BLAST software
available online (www.ncbi.nlm.nih.gov/BLAST).
Cloning of SHV gene
The blaSHV PCR product was purified using microcol-
umns of the Microspin Sephacryl S-400 purification sys-
tem (Amersham Biosciences). Purified DNA were ligated
into pGEM-T easy PCR cloning vector and transformed
into a competent cell of E. coli DH5α according to the
manufacturer’s instructions (Promega, WI). Positive col-
onies were selected on LB agar plates supplemented with
ampicillin (100 μg/ml)®. Plasmids were isolated using the
Rapid Plasmid miniprep system and digested with EcoRI
restriction enzyme (New England Biolabs) to confirm the
presence of the insert. The insert sequences were per-
formed on both strands by using forward and reverse
primers: UM11F (5′-CACCTTGCCGACGCAATGAC-
3′) and UM11 R (5′-TTAGCGTTGCCAGTGCTCG -3′),
an automated fluorescent method based on dye termin-
ator chemistry (AmpliTaq DNA polymerase FS Dye Ter-
minator Cycle Sequencing Ready Reaction Kit; Applied
Biosystems) and ABI Prism 3100 automated sequencer
(Applied Biosystems, USA). A similarity search of theTable 1 Sequences of the primers used to detect β-lactamase
PCR target Primer name Primer sequence 5′
CTX-M CTX-M-A CGCTTTGCGATGTGCA
CTX-M-B ACCGCGATATCGTTGG




OXA OXA-1 F CACAATACATATCAAC
OXA-1R GTGTGTTTAGAATGGTsequence was carried out using the BLAST program avail-
able at the NCBI BLAST homepage (www.ncbi.nlm.nih.
gov/blast/).Nucleotide sequence accession number
The nucleotide sequence of the blaSHV-128 gene has been
submitted to the EMBL-GenBank database and has been
assigned accession number GU932590.Results
The clinical strain of E. cloacae BF1417 included in this
study was isolated in the ICU of a Military hospital in
Tunisia during 2009. Antimicrobial tests showed that
the isolate was resistant to all β-lactams tested except
imipenem. Resistance to other drugs, including chloram-
phenicol, Tetracyclin, aminoglucosides and quinolones,
was observed. By filter mating, all the above resistance
determinants except cefoxitin, chloramphenicol and Tet-
racyclin were transferred to E.coli HB101 and were car-
ried on IncFII type plasmid of about 100-kb. The
transconjugants expressed high resistance to broad-
spectrum beta-lactams and gave positive results with the
DDST, indicating the production of ESBL. Resistance to
other antimicrobial agents was also transferred with the
plasmid suggesting their presence in a same genetic con-
text. The MICs of various antibiotics tested for donors,
transconjugants, and E.coli HB101 are summarized in
Table 2. MICs values revealed similar resistance profiles
for most β-lactams in transconjugants and the clinical
strain except the resistance to cefoxitin. When clavulanic
acid was combined with cefotaxime and cefdazidime, a
reduction in the MICs of these drugs was observed
(Table 2). Interestingly, the quinolone resistance pheno-
type of the transconjugants was identical to this of the
donor strain except for nalidixic acid. Indeed, the trans-
conjugants exhibited a reduction in the CMIs from
256 μg/ml to 32 μg/ml which could be due to other fac-
tors such as chromosomal gene mutations Such as al-
terations in the targets of quinolones, and decreased
accumulation inside the bacteria due to impermeabilitys genes









Table 2 Minimum inhibitory concentrations (MICs) of
various antimicrobial agents obtained for the clinical
isolate of E.cloacae and transconjugants
Antibiotics Minimum inhibitory concentration (μg/ml)
E.cloacae BF1417 E.coli HB101 HB101x pBF1417
Ampicillin >512 4 >512
Ticarcillin >256 2 >256
Cefoxitin >512 2 4








Cefpirome 8 2 8
Aztreonam 256 1 256
Nalidixic acid 256 1 32
Ciprofloxacin 32 1 16
Tetracyclin >512 2 2
Cloramphenicol >256 2 2







Figure 1 SDS-PAGE gel analysis of SHV-128 from Escherichia coli
HB101. Lane M: molecular mass standards; lane 1: before Sephadex
G-75 column, lane 2: after dialysis of active fraction, lane 3: after
polyacrylamide gel analysis.
Table 3 Substrate profiles of SHV-128 compared to those
of SHV- 2 and SHV-12 enzymes
Relative Vmax
SHV-2 SHV-12 SHV-128
Penzylpenicillin 100 100 76
Cephaloridine 123 214 ND
Ceftazidime <1 16 17
Cefotaxime 27 42 56
Aztreonam 11 110 140
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pump systems [19].
Analytical isoelectric focusing of crude extract of E.clo-
acae BxF1417 and its transconjugants revealed the pres-
ence of an identical β-lactamase band with a pI value
greater than 8.6. This activity was revealed with cefotax-
ime as substrates, which confirms that this was an
ESBL.The purity was verified by SDS-PAGE (Figure 1),
relative hydrolysis rates of this enzyme for benzylpenicil-
lin, cefotaxime, ceftazidime, and aztreonam are shown in
Table 3. The substrate profile of SHV-128 was compared
with those of SHV-12 and SHV-2, the first described
ESBL. Compared with SHV-12, SHV-128 showed an in-
creasing hydrolysis rate for cefotaxime and, in particular,
aztreonam. The hydrolysis rate of ceftazidime was simi-
lar to those of SHV-12. However, the Vm value of the
SHV-128 enzyme was lower for benzylpenicillin than
those of ceftazidime and cefotaxime. Such behavior illus-
trates well the extended-spectrum activity of SHV-128
enzyme. Inhibition studies showed that SHV-128 was
strongly inhibited by clavulanic acid, with IC50 =
4.2 μM.
Polymerase chain reaction (PCR) amplification did not
yield any products except for the bla SHV gene for both,
clinical isolate and transconjugants. The PCR products
were purified and cloned into pGEM-T Easy cloning
vector and transformed into E. coli DH5α. The plasmid,
pGEM-128, was extracted and the sequence of the PCR-
generated insert was determined on both strands. Se-
quence data of SHV-128 revealed an ORF of 861 pbencoding a protein product with 286 amino acid resi-
dues. Compared with the reported sequences of blaSHV-
1from GenBank, the resulting sequence revealed a novel
SHV-1 variant that was identical to blaSHV-1 except for
five point mutations, A(351)G, T(355)C, T(827)C,
C(828)T and T(8229) C, which was designated SHV-128
(Figure 2). Analysis of the SHV-128 and SHV-1 amino
acid sequences revealed 3 amino acid substitutions in
the coding region (cystein to arginin at position 123, iso-
leucine to threonine at position 282 and leucine to pro-
line at position 286). PCR mapping and sequencing
revealed that the blaSHV-128 gene, identified in the clin-
ical isolate ant transconjugants, was enclosed by inser-
tion sequence (IS) IS26 which were detected both
upstream and downstream of the reported gene. Thus,
the plasmid location of blaSHV-128 could facilitate its
spread especially since this gene is enclosed by inser-
tion sequence (IS) IS26 and associated with other re-
sistant genes.
Figure 2 Nucleotides sequence alignment of the blaSHV-128 gene from E.cloacae BF 1417 with the published bla SHV-1 variant.
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The present study report the phenotypic and molecular
characterization of a novel extended-spectrum SHV-type
β-lactamase, designated here as SHV-128. The amino
acid sequence of SHV-128 differs from the amino acid
sequence of SHV-1 by three amino acid substitutions:
cystein for arginin at position 123, isoleucine for threo-
nine at position 282 and leucine for proline at position
286. To our knowledge, these substitutions are observed
for the first time in a natural mutant SHV-type β-
lactamase (http://www.lahey.org/studies/). According to
the phenotypic analysis, the resulting new enzyme in-
duced a resistance phenotype compatible with that of an
ESBL. Indeed, the susceptibility pattern showed that the
enzyme caused resistance to C3G such as ceftazidime
and cefotaxime and is inhibited by the β-lactamase in-
hibitor clavulanic acid. Furthermore, the clinical isolate
and the transconjugants gave positive results with the
DDST, indicating the production of ESBL. SHV-128 was
located on a conjugative plasmid IncFII type of about
100-kb. The presence of resistance genes on plasmids and
transposable elements allows the genes to be transferred to
distantly related bacteria by conjugation, transduction, or
transformation [20-23]. In fact, several studies have been
conducted to evaluate the effect of promoter mutation orreplacement on the ESBL expression, especially those de-
livered by insertion sequences IS which the case here [24].
Generally, substitutions at positions 240 and 238 seem
to be especially critical for ESBL activity and occur in
the vast majority of SHV-type ESBL. Indeed, previous
experiments on SHV β-lactamases have reported that
G238S and E240K mutations are involved in conferring
resistance to C3G [25-27]. On the basis of its amino acid
sequence, SHV-128 includes these residus and contains
the 70SXXK73 tetrad, characteristic of β-lactamases pos-
sessing a serine active site. Two structural motifs charac-
teristic of class A β-lactamases, were also found to be
present in this novel variant: SDN at position 130–132
and KTG at position 234–236 [28]. Also, analysis of
SHV-128 structure model (results not cited) showed that
C123R mutation is not far from the SDN element that
span over active site residues. According to previous
studies [29], the arginine residu can induce changes in
the electrostatic interactions in an additional manner,
which might be a factor in enhancing the stability of
the protein. The change of the pI and the extended
spectrum of the enzyme could be attributed to the three
natural mutations reported here. However, in order to
analyze the role of these substitutions, a site-directed
mutagenesis analysis should be done. Furthermore,
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quired for better characterization of the SHV-128 en-
zyme and to specify the effect of each mutation on the
active site of the enzyme and its substrate profile. The
results obtained in the present study suggest that con-
tinuous mutation has led to the occurrence of novel
blaSHV ESBL gene variants. On the other hand, the pres-
ence of the insertion sequences IS suggests that resist-
ance associated with SHV production can contribute to
the dissemination of these emerging genes into other
nosocomial pathogens.
Conclusion
In conclusion, the present study explored the molecular
basis of antibiotic resistance in a clinical isolate originating
from Tunisian hospitals. The data revealed a novel SHV-
type β-lactamase, SHV-128. This protein possessed the
conserved class A β-lactamase motifs and hydrolyzed
oxyimino-cephalosporins as well as aztreonam, conferring
resistance to these agents. blaSHV-128 was bounded by IS26,
which facilitated its acquisition and its transfer among spe-
cies in the hospital. These finding highlights the genetic
plasticity of the SVH-type. β-lactamases and the remark-
able adaptability of Enterobacteriaceae species to selective
antibiotic pressure.
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